On demand slides

Patient-derived Organoids: Transforming Infectious Disease Research and Drug Development

At IDWeek 2025, our Chief Scientific Officer shared how HUB Organoids are redefining the landscape of infectious disease research. The presentation highlights the power of organoid technology to bridge the translational gap - bringing more predictive, patient-relevant insights to drug discovery and development.

From modeling respiratory infections like RSV and Rhinovirus to enabling targeted antiviral testing, HUB’s airway organoid platform showcases how science and innovation can accelerate the path toward new therapies and vaccines.

Download the slides to learn:

• How HUB’s patient-derived organoids replicate real human tissue biology
• Insights into RSV and Rhinovirus infection modeling using airway organoids
• How organoid-based systems shorten drug development timelines
• The latest breakthroughs driving HUB’s infectious disease platform